[go: up one dir, main page]

EA201591807A1 - Способы изготовления образцов для контроля содержания с-концевого лизина, галактозы и сиаловой кислоты в рекомбинантных белках - Google Patents

Способы изготовления образцов для контроля содержания с-концевого лизина, галактозы и сиаловой кислоты в рекомбинантных белках

Info

Publication number
EA201591807A1
EA201591807A1 EA201591807A EA201591807A EA201591807A1 EA 201591807 A1 EA201591807 A1 EA 201591807A1 EA 201591807 A EA201591807 A EA 201591807A EA 201591807 A EA201591807 A EA 201591807A EA 201591807 A1 EA201591807 A1 EA 201591807A1
Authority
EA
Eurasian Patent Office
Prior art keywords
content
sialic acid
lysin
galactose
methods
Prior art date
Application number
EA201591807A
Other languages
English (en)
Inventor
Марсель Фликвеерт
Чарльз Гучи
Франсис Масланка
Францискус Йоханнес Игнатиус Нагель
Джеймс Райланд
Юджин Шефер
Original Assignee
Янссен Байотек, Инк.
Янссен Байолоджикс Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51528780&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201591807(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Янссен Байотек, Инк., Янссен Байолоджикс Б.В. filed Critical Янссен Байотек, Инк.
Publication of EA201591807A1 publication Critical patent/EA201591807A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)

Abstract

В настоящем патенте раскрывается способ создания антитела, например анти-ФНО-α-антитела (т.е. инфликсимаб), имеющего содержание С-концевого лизина от 20 до 70%, содержание сиаловой кислоты от 1 до 20%, содержащего цинкреагирующие клетки-хозяева, трансфицированные ДНК, кодирующей антитело в культурной среде, содержащей по меньшей мере 0,5 мкмоль/л цинка, и контроль концентрации цинка в культурной среде для создания антитела.
EA201591807A 2013-03-15 2014-03-07 Способы изготовления образцов для контроля содержания с-концевого лизина, галактозы и сиаловой кислоты в рекомбинантных белках EA201591807A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361791094P 2013-03-15 2013-03-15
PCT/US2014/021574 WO2014149935A1 (en) 2013-03-15 2014-03-07 Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins

Publications (1)

Publication Number Publication Date
EA201591807A1 true EA201591807A1 (ru) 2016-02-29

Family

ID=51528780

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591807A EA201591807A1 (ru) 2013-03-15 2014-03-07 Способы изготовления образцов для контроля содержания с-концевого лизина, галактозы и сиаловой кислоты в рекомбинантных белках

Country Status (27)

Country Link
US (3) US20140273092A1 (ru)
EP (1) EP2970980B2 (ru)
JP (1) JP2016512029A (ru)
KR (1) KR102216003B1 (ru)
CN (1) CN105378086B (ru)
AR (2) AR095660A1 (ru)
AU (2) AU2014237635B2 (ru)
BR (1) BR112015022971B1 (ru)
CA (1) CA2907140A1 (ru)
CY (1) CY1120980T1 (ru)
DK (1) DK2970980T3 (ru)
EA (1) EA201591807A1 (ru)
ES (1) ES2690047T3 (ru)
HR (1) HRP20181741T1 (ru)
IL (1) IL240689B (ru)
LT (1) LT2970980T (ru)
MX (1) MX366910B (ru)
PH (1) PH12015501837B1 (ru)
PL (1) PL2970980T3 (ru)
PT (1) PT2970980T (ru)
RS (1) RS57791B1 (ru)
SG (1) SG11201507577RA (ru)
SI (1) SI2970980T1 (ru)
SM (1) SMT201800550T1 (ru)
TW (1) TWI630216B (ru)
WO (1) WO2014149935A1 (ru)
ZA (1) ZA201507671B (ru)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014143205A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014149935A1 (en) * 2013-03-15 2014-09-25 Janssen Biotech, Inc. Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins
KR102118240B1 (ko) 2013-08-20 2020-06-03 레크 파마슈티칼스 디.디. 폴리펩티드의 α-아미드화 및/또는 C-말단 아미노산 분열의 제어를 위한 세포 배양 매질 및 방법
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EA201891093A1 (ru) 2015-11-03 2018-10-31 Янссен Байотек, Инк. Антитела, специфически связывающие pd-1, и их применение
JP2018536404A (ja) * 2015-11-09 2018-12-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｈｏ細胞において産生したポリペプチドの品質特性を操作する方法
JP2019502698A (ja) 2015-12-17 2019-01-31 ヤンセン バイオテツク，インコーポレーテツド Ｈｌａ−ｄｒに特異的に結合する抗体及びその使用
US11719704B2 (en) 2015-12-30 2023-08-08 Momenta Pharmaceuticals, Inc. Methods related to biologics
KR102554331B1 (ko) 2016-08-12 2023-07-10 얀센 바이오테크 인코포레이티드 향상된 효능적 활성을 갖는 Fc 조작된 항-TNFR 수퍼패밀리 구성원 항체 및 그의 사용 방법
CN109863170B (zh) 2016-08-12 2024-08-16 詹森生物科技公司 具有增强的激动作用和效应子功能的工程化抗体及其他含Fc结构域分子
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
AU2018281045A1 (en) 2017-06-05 2019-12-12 Janssen Biotech, Inc. Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations
KR102692379B1 (ko) 2017-06-05 2024-08-05 얀센 바이오테크 인코포레이티드 Pd-1과 특이적으로 결합하는 항체 및 사용 방법
WO2019077628A1 (en) * 2017-10-16 2019-04-25 Council Of Scientific & Industrial Research ZINC SUPPLEMENTATION TO DECREASE GALACTOSYLATION OF RECOMBINANT GLYCOPROTEINS
CA3101304A1 (en) 2018-05-24 2019-11-28 Janssen Biotech, Inc. Monospecific and multispecific anti-tmeff2 antibodies and their uses
CN113474366B (zh) * 2018-12-31 2025-01-17 动量制药公司 产生优特克单抗的方法
JP2022541332A (ja) 2019-07-26 2022-09-22 ヤンセン バイオテツク，インコーポレーテツド カリクレイン関連ペプチダーゼ２抗原結合ドメインを含むタンパク質及びその使用
CR20220054A (es) 2019-08-15 2022-06-06 Janssen Biotech Inc Materiales y métodos para fragmentos variables de cadena única mejorado
BR112022018176A2 (pt) 2020-03-13 2022-12-06 Janssen Biotech Inc Materiais e métodos para ligação de siglec-3/cd33
CA3184189A1 (en) 2020-05-27 2021-12-02 Janssen Biotech, Inc. Proteins comprising cd3 antigen binding domains and uses thereof
AR123083A1 (es) 2020-07-29 2022-10-26 Janssen Biotech Inc Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos
TW202231292A (zh) 2020-10-13 2022-08-16 美商健生生物科技公司 用於調節分化簇ｉｖ及／或ｖｉｉｉ的經生物工程改造之ｔ細胞介導之免疫力、材料、及其他方法
IL302277A (en) 2020-10-22 2023-06-01 Janssen Biotech Inc Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses
CA3210246A1 (en) 2021-01-28 2022-08-04 Janssen Biotech, Inc. Psma binding proteins and uses thereof
US12180278B2 (en) 2021-03-24 2024-12-31 Janssen Biotech, Inc. Antibody targeting CD22 and CD79B
MX2023011266A (es) 2021-03-24 2023-12-07 Janssen Biotech Inc Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de estas.
CA3229822A1 (en) 2021-09-13 2023-03-16 Patrick John DOONAN Cd33 x v?2 multispecific antibodies for the treatment of cancer
EP4405392A1 (en) 2021-09-24 2024-07-31 Janssen Biotech, Inc. Proteins comprising cd20 binding domains, and uses thereof
EP4436669A1 (en) 2021-11-22 2024-10-02 Janssen Biotech, Inc. Compositions comprising enhanced multispecific binding agents for an immune response
WO2024089551A1 (en) 2022-10-25 2024-05-02 Janssen Biotech, Inc. Msln and cd3 binding agents and methods of use thereof
US20250136688A1 (en) 2023-08-07 2025-05-01 Janssen Biotech, Inc. Stabilized cd3 antigen binding agents and methods of use thereof
WO2025032508A1 (en) 2023-08-07 2025-02-13 Janssen Biotech, Inc. Enpp3 and cd3 binding agents and methods of use thereof
WO2025137410A1 (en) * 2023-12-20 2025-06-26 Apogee Therapeutics, Inc. Pharmaceutical compositions of anti-il-13 antibodies with and without c-terminal lysine

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
JP2647427B2 (ja) 1987-04-24 1997-08-27 帝人株式会社 被検者の病態の判定のための検出方法、モノクロ−ナル抗体および検出キット
WO1991002078A1 (en) 1989-08-07 1991-02-21 Peptide Technology Ltd Tumour necrosis factor binding ligands
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
EP0610201B2 (en) * 1991-03-18 2007-09-26 New York University Monoclonal and chimeric antibodies specific for human tumor necrosis factor
FR2807767B1 (fr) † 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
UA81743C2 (ru) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНОЕ АНТИТЕЛО ЧЕЛОВЕКА, КОТОРОЕ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С ФАКТОРОМ НЕКРОЗА ОПУХОЛЕЙ АЛЬФА (ФНПα), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ЕГО СОДЕРЖИТ, И СПОСОБ ЛЕЧЕНИЯ РЕВМАТОИДНОГО АРТРИТА
CA2450289A1 (en) † 2003-03-20 2005-05-19 Imclone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
US20040185047A1 (en) 2003-03-21 2004-09-23 Jill Giles-Komar Anti- TNF antibodies, compositions, methods and uses
CA2583027A1 (en) † 2004-11-02 2006-10-19 Ares Trading S.A. Serum-free cell culture medium for mammalian cells
CA2720610C (en) * 2008-04-07 2016-08-23 Bayer Healthcare Llc Methods of recombinant production of glycoproteins
WO2012147053A1 (en) * 2011-04-29 2012-11-01 Biocon Research Limited A method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof
US9475858B2 (en) 2011-07-08 2016-10-25 Momenta Pharmaceuticals, Inc. Cell culture process
US9181572B2 (en) * 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2014149935A1 (en) * 2013-03-15 2014-09-25 Janssen Biotech, Inc. Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins

Also Published As

Publication number Publication date
MX366910B (es) 2019-07-30
WO2014149935A1 (en) 2014-09-25
IL240689A0 (en) 2015-10-29
KR102216003B1 (ko) 2021-02-16
JP2016512029A (ja) 2016-04-25
CY1120980T1 (el) 2019-12-11
SG11201507577RA (en) 2015-10-29
US11149085B2 (en) 2021-10-19
MX2015012361A (es) 2016-04-28
SI2970980T1 (sl) 2018-11-30
PH12015501837B1 (en) 2022-02-11
US20220089712A1 (en) 2022-03-24
AU2020203864B2 (en) 2022-05-26
US20140273092A1 (en) 2014-09-18
AU2020203864A1 (en) 2020-07-02
TW201441263A (zh) 2014-11-01
BR112015022971B1 (pt) 2022-05-17
ES2690047T3 (es) 2018-11-19
CN105378086A (zh) 2016-03-02
SMT201800550T1 (it) 2019-01-11
KR20150129025A (ko) 2015-11-18
US20160237149A1 (en) 2016-08-18
EP2970980A4 (en) 2016-09-07
EP2970980A1 (en) 2016-01-20
EP2970980B1 (en) 2018-08-15
PT2970980T (pt) 2018-11-19
CA2907140A1 (en) 2014-09-25
DK2970980T3 (en) 2018-10-22
HRP20181741T1 (hr) 2018-12-28
EP2970980B2 (en) 2022-07-27
AR095660A1 (es) 2015-11-04
PL2970980T3 (pl) 2019-01-31
LT2970980T (lt) 2018-10-25
AR124871A2 (es) 2023-05-17
IL240689B (en) 2021-12-01
TWI630216B (zh) 2018-07-21
AU2014237635B2 (en) 2020-03-12
RS57791B1 (sr) 2018-12-31
BR112015022971A2 (pt) 2017-11-14
ZA201507671B (en) 2017-11-29
AU2014237635A1 (en) 2015-09-03
PH12015501837A1 (en) 2015-11-09
CN105378086B (zh) 2019-05-28

Similar Documents

Publication Publication Date Title
EA201591807A1 (ru) Способы изготовления образцов для контроля содержания с-концевого лизина, галактозы и сиаловой кислоты в рекомбинантных белках
MX2023001360A (es) Anticuerpos anti-c5 y metodos de uso.
SA518391704B1 (ar) C5 أجسام مضادة لـ وطرق لاستخدامها
EA201690600A1 (ru) Метаболически оптимизированная клеточная культура
MY183415A (en) Anti-c5 antibodies and methods of use
FI3536797T3 (fi) Siirtogeenin tehostettu ilmentäminen ja prosessointi
MX2020008470A (es) Vectores de adn no virales y usos de estos para la produccion de anticuerpos y proteinas de fusion.
MX2013000899A (es) Proceso para purificar proteinas.
MX2020003798A (es) Metodos para la purificacion de arilsulfatasa a.
AR095418A1 (es) Métodos para aumentar el contenido de manosa en proteínas recombinantes
EA201270015A1 (ru) Рефолдинг белков с использованием химически контролируемого окислительно-восстановительного состояния
RU2020115514A (ru) Контролирование образования дисульфидных связей в белковых растворах с помощью добавления восстанавливающих средств
EA201000945A1 (ru) Конструирование системы секреции на основе sm-белков
Viader‐Salvadó et al. Shrimp (Litopenaeus vannamei) trypsinogen production in Pichia pastoris bioreactor cultures
EA201591558A1 (ru) Составы и способы увеличения производства рекомбинантного белка
DE602007012053D1 (de) Affinitätspolypeptid zur reinigung von rekombinanten proteinen
MX394035B (es) Procedimiento para preparar una proteina de fusion tnfr-fc que contiene un contenido objetivo de impurezas.
MX2024003411A (es) Métodos para controlar la heterogeneidad de anticuerpos.
WO2012140588A8 (en) Production of heterologous extracellular polypeptides in yarrowia lipolytica
Joung et al. Analysis for Residual Host Cell Proteins in Process Streams of Recombinant Anti GPIIbIIIa Antibody
EP4379047A3 (en) Stock solution of retrovirus like particles with method